Pulmatrix Announces Commercial Launch of FEND

Pulmatrix announced marketing and distribution partner Sensory Cloud's commercial launch of FEND, a hypertonic calcium chloride salt solution with nasal mister. FEND is a potentially important new hygiene option beyond masks to combat the ongoing COVD-19 pandemic. Pulmatrix licensed the rights to the Company's NasoCalm proprietary formulations (PUR003 and PUR006) to Sensory Cloud, now integral to the product FEND, with Sensory Cloud to market and distribute FEND, and Pulmatrix to receive escalating royalties, upon commencement of sales.

FEND, and the earlier Pulmatrix NasoCalm formulations have been shown through a series of peer-reviewed publications to reduce respiratory droplets from the airways by placing calcium-rich saline on the surface of mucus, which otherwise tends to lose strength and breakup in the presence of infection. In a recent publication of the journal Molecular Frontiers, study results showed that FEND lowered exhaled aerosol particles by up to 99% for up to 6 hours with an overall 75% reduction of exhaled particles at 30 minutes post-administration.  Importantly, FEND has the potential to address airborne submicron droplets not captured by surgical masks that may increase infection threat, particularly in indoor environments.

Ted Raad, Chief Executive Officer of Pulmatrix Said: "There is a growing body of scientific evidence that FEND, delivered by Sensory Cloud's FEND Mister, has the ability to reduce bioaerosol production, addressing even the smallest aerosol particles not blocked by masks. This commercial launch is an important milestone for Pulmatrix, leveraging our work in developing NasoCalm, now formulated and distributed as FEND to help combat the ongoing COVD-19 pandemic, We believe the global launch of FEND, if successful, could provide a new source of revenue to enable the advancement of our iSPERSE™ platform of inhaled therapies and we are thrilled to have played a role in bringing this product to the public."

SOURCE Pulmatrix, Inc.

Related Posts

Subscribe Our Newsletter